Helicobacter pylori immunoproteomics in gastric cancer and gastritis of the carcinoma phenotype

Expert Review of Proteomics

Volumn 7, Issue 2, 2010, Pages 239-248

  Lahner, Edith ^a   Bernardini, Giulia ^b   Santucci, Annalisa ^b   Annibale, Bruno ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Atrophic gastritis; Gastric cancer; Gastritis of the carcinoma phenotype; Helicobacter pylori; Immunoblotting; Immunoproteomics; Proteomics

Indexed keywords

BACTERIAL ANTIGEN;

CANCER PREVENTION; CLINICAL RESEARCH; DISEASE COURSE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PHENOTYPE; PROTEOMICS; REVIEW; RISK FACTOR; STOMACH CANCER;

ANIMALS; CARCINOMA; GASTRITIS; HELICOBACTER PYLORI; HUMANS; MODELS, BIOLOGICAL; PROTEOMICS; RISK FACTORS; STOMACH NEOPLASMS;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

EID: 77950842907     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.10.5     Document Type: Review

References (90)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N. Engl. J. Med. 347, 1175-1186 (2002).
2. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat. Rev. Cancer 2, 28-37 (2002).
3. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 9(Suppl. 2), 45-51 (1995).
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
5. Marshall BJ, Windsor HM. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: pathophysiology, epidemiology, screening, clinical presentaion, treatment, and prevention. Med. Clin. North Am. 89, 313-344 (2005).
6. Graham DY. Helicobacter pylori infection is the primary cause of gastric cancer. J. Gastroenterol. 35(Suppl. 12), 90-97 (2000).
7. Covacci A, Censini S, Bugnoli M et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc. Natl Acad. Sci. USA 90(12), 5791-5795 (1993).
8. Bagnoli F, Buti L, Tompkins L, Covacci A, Amieva MR. Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells. Proc. Natl Acad. Sci. USA 102(45), 16339-16344 (2005).
9. Svennerholm A-M, Lundgren A. Progess in vaccine development against Helicobacter pylori. FEMS Immunol. Med. Microbiol. 50, 146-156 (2007).
10. Kusters JG, Van Vliet AHM, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin. Microbiol. Rev. 19, 449-490 (2006).
11. Algood HM, Cover TL. Helicobacter pylori persistence: an overview of interactions between H. pylori and host immune defenses. Clin. Microbiol. Rev. 19, 597-613 (2006).
12. Smythies LE, Waites KB, Lindsey JR, Harris PR, Ghiara P, Smith PD. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-g gene-deficient mice. J. Immunol. 165, 1022-1029(2000).
13. Vorobjova T, Nilsson I, Kull K et al. CagA protein seropositivity in a random sample of adult population and gastric cancer patients in Estonia. Eur. J. Gastroenterol. Hepatol. 10(1), 41-46 (1998).
14. Said Essa A, Alaa Eldeen Nouh M, Mohammed Ghaniam N, Graham DY, Said Sabry H. Prevalence of cagA in relation to clinical presentation of Helicobacter pylori infection in Egypt. Scand. J. Infect. Dis. 40(9), 730-733 (2008).
15. Palli D, Masala G, Del Giudice G et al. CagA Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int. J. Cancer 120(4), 859-867 (2007).
16. Beales IL, Crabtree JE, Scunes D, Covacci A, Calam J. Antibodies to CagA protein are associated with gastric atrophy in Helicobacter pylori infection. Eur. J. Gastroenterol. Hepatol. 8(7), 645-649 (1996).
17. O'Keeffe, Moran AP. Conventional, regulatory, and unconventional T cells in the immunologic response to Helicobacter pylori. Helicobacter 13, 1-19 (2008).
18. Scalzo K, Plebanski M, Apostolopoulos V. Regulatory T-cells: immunomodulators in health and disease. Curr. Top. Med. Chem. 6, 1759-1768 (2006).
19. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat. Rev. Immunol. 4, 841-855 (2004).
20. Enarsson K, Lundgren A, Kindlund B et al. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. Clin. Immunol. 121, 358-368 (2006).
21. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Res. 52, 673-675 (1992).
22. Haber MM. Histologic precursors of gastrointestinal tract malignancy. Gastroenterol. Clin. North Am. 31, 395-419 (2002).
23. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori and the development of gastric cancer. N. Engl. J. Med. 345, 784-789 (2001).
24. Kuipers EJ, Uyterlinde AM, Pena AS et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 345, 1525-1528 (1995).
25. Annibale B, Negrini R, Caruana P et al. Two thirds of patients with atrophic body gastritis have evidence of Helicobacter pylori infection. Helicobacter 6, 225-233 (2001).
26. Tatsuta M, Iishi H, Nakaizumi A et al. Fundal atrophic gastritis as a risk factor for gastric cancer. Int. J. Cancer 53, 70-74 (1993).
27. Wu M-S, Chen C-J, Lin J-T. Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiol. Biomarkers Prev. 14, 1878-1882 (2005).
28. De Vries AC, Van Grieken NC, Looman CW et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 134(4), 945-952 (2008).
29. Vannella L, Lahner E, Bordi C et al. Prevalence, incidence and risk factors for gastric neoplastic lesions in patients with atrophic body gastritis. Digest. Liv. Dis. (41), S116-S117 (2009).
30. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic pattern of intestinal metaplasia and gastric cancer. Am. J. Gastroenterol. 95, 1431-1438 (2000).
31. Annibale B, Lahner E. Assessing the severity of atrophic gastritis. Eur. J. Gastroenterol. Hepatol. 19, 1059-1063 (2007).
32. Lahner E, Bordi C, Cattaruzza MS et al. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 22, 471-481 (2005).
33. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum. Pathol. 36, 228-233 (2005).
34. Meining A, Morgner A, Miehlke S, Bayerdörffer E, Stolte M. Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis? Best Pract. Res. Clin. Gastroenterol. 15, 983-998 (2001).
35. Hansson L-E, Nyren O, Hsing AW et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N. Eng. J. Med. 335, 242-249 (1996).
36. El-Omar ME, Oien K, Murray LS et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of Helicobacter pylori. Gastroenterology 118, 22-30 (2000).
37. Eisenbrand G, Adam B, Peter M, Malfertheiner P, Schlag P. Formation of nitrite in gastric juice of patients with various gastric disorders after ingestion of a standard dose of nitrate: a possible risk factor for gastric carcinogenesis. IARC Sci. Publ. 57, 963-968 (1984).
38. Annibale B, Capurso G, Lahner E et al. Concomitant alterations in intragastric pH and ascorbic acid concentration in patients with Helicobacter pylori gastritis and associated iron deficiency anaemia. Gut 52, 496-501 (2003).
39. Beales IP, Calam J. Interleukin 1b and tumour necrosis factor a inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut 42, 227-234 (1998).
40. Noach LA, Bosma NB, Jansen J, Hoek FJ, Van Deventer SJ, Tytgat GN. Mucosal tumor necrosis factor-a, interleukin-1b, and interleukin-8 production in patients with Helicobacter pylori infection. Scand. J. Gastroenterol. 29, 425-429 (1994).
41. Yamaoka Y, Kita M, Kodama T, Sawai N, Imanishi J. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 110, 1744-1752 (1996).
42. El-Omar EM, Carringtom M, Chow WH et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404, 398-402 (2000).
43. Rad R, Prinz C, Neu B et al. Synergistic effect of Helicobacter pylori virulence factors and interleukin-1 polymorphisms for the development of severe histological changes in the gastric mucosa. J. Infect. Dis. 188, 272-281 (2003).
44. Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H. Interleukin 1b polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 123, 92-105 (2002).
45. Camargo MC, Mera R, Correa P et al. Interleukin-1b and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 15, 1674-1687 (2006).
46. Lahner E, Corleto VD, D'Ambra G, Di Giulio E, Delle Fave G, Annibale B. Is interleukin-1 genotyping useful for the clinical management of patients with atrophic body gastritis? Aliment. Pharmacol. Ther. 27, 355-365 (2008).
47. Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2002. In: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base no.5 version 2.0, IARC Press, Lyon, France (2004).
48. Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer. 80, 2333-2341 (1997).
49. Wong BC, Lam SK, Wong WM et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291, 187-194 (2004).
50. Del Giudice G, Malfertheiner P, Rappuoli R. Development of vaccines against Helicobacter pylori. Expert Rev. Vaccines 8(8), 1037-1049 (2009).
51. Kabir S. The current status of Helicobacter pylori vaccines: a review. Helicobacter 12, 89-102 (2007).
52. Rugge M. Secondary prevention of gastric cancer. Gut 56, 1646-1647 (2007).
53. Dixon MF, Genta RM, Yardley JH et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am. J. Surg. Pathol. 20, 1161-1181 (1996).
54. Rugge M, Cassaro M, Pennelli G et al. Atrophic gastritis: pathology and endoscopy in the reversibility assessment. Gut 52(9), 1387-1388 (2003).
55. Väänänen H, Vauhkone M, Helske T et al. Nonendoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur. J. Gastroenterol. Hepatol. 15, 885-891 (2003).
56. Derakhshan MH, El-Omar E, Oien K et al. Gastric histology, serological markers and age as predictors of gastric acid secretion in patients infected with Helicobacter pylori. J. Clin. Pathol. 59(12), 1293-1299 (2006).
57. Di Mario F, Cavallaro LG, Moussa AM et al. Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium. Dig. Dis. Sci. 51(10), 1791-1795 (2006).
58. Graham DY, Nurgalieva ZZ, El-Zimaity HM et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin. Gastroenterol. Hepatol. 4(3), 306-314 (2006).
59. Kuipers, EJ. In through the out door: serology for atrophic gastritis. Eur. J. Gastroenterol. Hepatol. 15(8), 877-879 (2003).
60. Nardone G, Rocco A, Staibano S et al. Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Aliment. Pharmacol. Ther. 22(11-12), 1139-1146 (2005).
61. Pasechnikov VD, Chukov SZ, Kotelevets SM et al. Invasive and non-invasive diagnosis of Helicobacter pylori-associated atrophic gastritis: a comparative study. Scand. J. Gastroenterol. 40(3), 297-301 (2005).
62. Ricci C, Vakil N, Rugge M et al. Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am. J. Gastroenterol. 99(10), 1910-1915 (2004).
63. Blaser MJ, Crabtree JE. CagA and the outcome of Helicobacter pylori infection. Am. J. Clin. Pathol. 106, 565-567 (1996).
64. Annibale B, Lahner E, Santucci A et al. CagA and VacA are immunoblot markers of past Helicobacter pylori infection in atrophic body gastritis. Helicobacter 12, 23-30 (2007).
65. Ekström AM, Held M, Hansson L-E, Engstrand L, Nyrén O. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 121, 784-791(2001).
66. Mini R, Annibale B, Lahner E, Bernardini G, Figura N, Santucci A. Western blotting of total lysate of Helicobacter pylori in cases of atrophic body gastritis. Clin. Chem. 52, 220-226 (2006).
67. Linz B, Balloux F, Moodley Y et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature 445(7130), 915-918 (2007).
68. Gao L, Michel A, Weck MN, Arndt V, Pawlita M, Brenner H. Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res. 69(15), 6164-6170 (2009).
69. Klade CS. Proteomics approaches towards antigen discovery and vaccine development. Curr. Opin. Mol. Ther. 4(3), 216-223 (2002).
70. Bernardini G, Braconi D, Lusini P, Santucci A. Helicobacter pylori: immunoproteomics related to different pathologies. Expert Rev. Proteomics 4(5), 679-689 (2007).
71. Sanchez-Campillo M, Bini L, Comanducci M et al. Identification of immunoreactive proteins of Chlamydia trachomatis by western blot analysis of a two-dimensional electrophoresis map with patient sera. Electrophoresis 20(11), 2269-2279 (1999).
72. Jungblut PR, Grabher G, Stöffler G. Comprehensive detection of immunorelevant Borrelia garinii antigens by two-dimensional electrophoresis. Electrophoresis 20(18), 3611-3622 (1999).
73. Nowalk AJ, Gilmore RD Jr, Carroll JA et al. Serologic proteome analysis of Borrelia burgdorferi membrane-associated proteins. Infect. Immun. 74(7), 3864-3873 (2006).
74. Vytvytska O, Nagy E, Blüggel M et al. Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics 2(5), 580-590 (2002). (Pubitemid 34507348)
75. Ariel N, Zvi A, Makarova KS et al. Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens. Infect. Immun. 71(8), 4563-4579 (2003).
76. Jungblut PR. Proteome analysis of bacterial pathogens. Microbes. Infect. 3(10), 831-840 (2001).
77. Kimmel B, Bosserhoff A, Frank R, Gross R, Goebel W, Beier D. Identification of immunodominant antigens from Helicobacter pylori and evaluation of their reactivities with sera from patients with different gastroduodenal pathologies. Infect. Immun. 68, 915-920 (2000).
78. Krah A, Miehlke S, Pleissner KP et al. Identification of candidate antigens for serologic detection of Helicobacter pylori-infected patients with gastric carcinoma. Int. J. Cancer 108, 456-463 (2004).
79. Jungblut PR, Bumann D, Haas G et al. Comparative proteome analysis of Helicobacter pylori. Mol. Microbiol. 36(3), 710-725 (2000).
80. Haas G, Karaali G, Ebermayer K et al. Immunoproteomics of Helicobacter pylori infection and relation to gastric disease. Proteomics 2, 313-324 (2002).
81. Mini R, Bernardini G, Salzano AM et al. Comparative proteomics and immunoproteomics of Helicobacter pylori related to different gastric pathologies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 833, 63-79 (2006).
82. Lin YF, Wu MS, Chang CC et al. Comparative immunoproteomics of identification and characterization of virulence factors from Helicobacter pylori related to gastric cancer. Mol. Cell. Proteomics 5, 1484-1496 (2006).
83. McAtee CP, Lim MY, Fung K et al. Identification of potential diagnostic and vaccine candidates of Helicobacter pylori by two-dimensional gel electrophoresis, sequence analysis, and serum profiling. Clin. Diagn. Lab. Immunol. 5(4), 537-542 (1998).
84. Lin YF, Chen CY, Tsai MH et al. Duodenal ulcer-related antigens from Helicobacter pylori: immunoproteome and protein microarray approaches. Mol. Cell. Proteomics 6(6), 1018-1026 (2007).
85. Falush D, Stephens M, Pritchard JK. Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 164(4), 1567-1587 (2003).
86. Lahner E, Santucci A, Bernardini G et al. Immunoproteomics of Helicobacter pylori allows to identify patients with gastritis a high risk for gastric cancer. Gut 56(Suppl. III), A104 (2007).
87. Forman D, Pisani P. Gastric cancer in Japan - honing treatment, seeking causes. N. Engl. J. Med. 359(5), 448-451 (2008).
88. Hunt JD, Mera R, Strimas A et al. KRAS mutations are not predictive for progression of preneoplastic gastric lesions. Cancer Epidemiol. Biomarkers Prev. 10(1), 79-80 (2001).
89. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. Helicobacter pylori virulence and genetic geography. Science 284(5418), 1328-1333 (1999).
90. Hynes SO, McGuire J, Wadström T. Potential for proteomic profiling of Helicobacter pylori and other Helicobacter spp. using a ProteinChip array. FEMS Immunol. Med. Microbiol. 36(3), 151-158 (2003).